ERBB2 and non-small cell lung carcinoma: Very recent preliminary data from DESTINY-Lung02/NCT04644237 (a phase II randomized dose-finding trial) showed that the ORR among a cohort of HER2-mutant NSCLC patients receiving 5.4 mg/kg of T-Dxd (n = 52) was 57.7%.